Summary of Vaxart's Presentation at Oppenheimer's 36th Annual Healthcare Conference Company Overview - **Company**: Vaxart - **Industry**: Biotechnology, specifically focusing on oral pill vaccines Core Points and Arguments 1. **Innovative Vaccine Platform**: Vaxart is pioneering a transformative approach to oral pill vaccines that generate both systemic and mucosal immunity, which is expected to revolutionize vaccine distribution and administration [2][3] 2. **Partnership with Dynavax**: A partnership with Dynavax was announced, which validates Vaxart's platform and extends its cash runway. This partnership includes a BARDA-funded COVID-19 vaccine and other vaccine opportunities [3][29] 3. **Pipeline Overview**: Vaxart has multiple vaccine programs, including: - A COVID-19 vaccine in Phase II testing, with top-line data expected soon [9][27] - A norovirus vaccine with promising data from previous studies [10][15] - An influenza vaccine with statistically significant results compared to existing vaccines [11][22] - A therapeutic HPV vaccine in preclinical development [12] 4. **Safety and Efficacy**: The oral pill vaccines have shown a safety profile comparable to placebo, with no injection site reactions. The mucosal immunity provided by the vaccine is seen as a potential advantage [5][6] 5. **Clinical Data**: - The COVID-19 vaccine study has enrolled 5,400 subjects, with a focus on safety and efficacy over a 12-month period [12][13] - The norovirus vaccine showed a 30% relative reduction in G11 and a 21% reduction in acute gastroenteritis in challenge studies [18] - The influenza vaccine demonstrated a 49% decrease in infection compared to placebo [22] 6. **Market Potential**: The norovirus represents a $10 billion annual economic burden in the U.S., highlighting the significant unmet need for effective vaccines [15][16] 7. **Future Milestones**: Vaxart is focused on completing its COVID-19 study and advancing its norovirus and influenza programs, with important milestones expected through 2027 [27][29] Additional Important Content 1. **Regulatory and Partnership Dynamics**: The acquisition of Dynavax by Sanofi is expected to enhance Vaxart's partnership dynamics, as Sanofi is a market leader in vaccines [30][36] 2. **Combination Vaccine Strategy**: Vaxart is exploring the potential for combination vaccines, which could allow for multiple strains or antigens to be included in a single oral pill [49][50] 3. **Expansion Opportunities**: The platform's ability to generate mucosal immunity positions Vaxart to explore vaccines for other pathogens that enter through mucosal surfaces, such as respiratory and gastrointestinal pathogens [47][48] This summary encapsulates the key points from Vaxart's presentation, highlighting the company's innovative approach, pipeline, and future opportunities in the biotechnology sector.